Association between serum C-reactive protein levels and clinical and laboratory characteristics of patients with polycythemia vera

Analysis of serum CRP levels in 197 patients with polycythemia vera revealed positive correlations with fibrinogen (rs=0,46, p<0,001), interleukin-6 (r=0,38, p<0,001), and erythrocyte sedimentation rate (rs=0,47, p<0,001). A notable association was identified between elevated CRP levels (>5 mg/l) and the frequency of increased D-dimer concentrations (Pearson’s χ2 test p=0,031). Additionally, a weak but detectable correlation was observed with hyperhomocysteinemia and decreased protein S levels, potentially contributing to thrombotic complications. CRP levels correlated significantly with leukocyte count (rs=0,20, p=0,034), particularly neutrophils (rs=0,23, p=0,012) and monocytes count (rs=0,26, p=0,004), as well as with uric acid levels (rs=0,26, p=0,005), gamma-glutamyl transferase activity (rs=0,25, p=0,006), and urea levels (rs=0,20, p=0,036). Elevated CRP values were more prevalent among patients with a history of cancer, diabetes mellitus, or coronary heart disease, although differences did not reach statistical significance.

1. Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood, 2012, no.14, pp.3219–25. https://doi.org/10.1182/blood-2011-11-394775

2. Tefferi A, Barbui T. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 2023, no.9, pp.1465–87. https://doi.org/10.1002/ajh.27002

3. Fisher DAC, Fowles JS, Zhou A, Oh ST. Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms. Frontiers in Immunology, 2021, vol.12, pp.1–26. https://doi.org/10.3389/fimmu.2021.683401

4. Lussana F, Rambaldi A. Inflammation and myeloproliferative neoplasms. Journal of Autoimmunity, Elsevier Ltd; 2017, vol.8, pp.58–63. https://doi.org/10.1016/j.jaut.2017.06.010

5. Bray C, Bell LN, Liang H, Haykal R, Kaiksow F, Mazza JJ, Yale SH. Erythrocyte sedimentation rate and C-reactive protein measurements and their relevance in clinical medicine. Wmj, 2016, no.6, pp.317–21.

6. Badimon L, Peña E, Arderiu G, Padró T, Slevin M, Vilahur G, Chiva-Blanch G. C-Reactive Protein in Atherothrombosis and Angiogenesis. Frontiers in Immunology, Frontiers; 2018, , pp.1–7. https://doi.org/10.3389/fimmu.2018.00430

7. Velkov VV. C-reactive protein in laboratory diagnostics of acute inflammation and risk assessment of vascular pathologies [C-reaktivnyj belok - v laboratornoj diagnostike ostryh vospalenij i v ocenke riskov sosudistyh patologij]. Clinical and laboratory consultation [Kliniko-laboratornyi konsilium], 2008, no.21, pp.37-48. (In Russian).

8. Lussana F, Carobbio A, Salmoiraghi S, Guglielmelli P, Vannucchi AM, Bottazzi B, Leone R, Mantovani A, Barbui T, Rambaldi A. Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. Journal of Hematology & Oncology, 2017, no.1, pp.54. https://doi.org/10.1186/s13045-017-0425-z

9. Barbui T, Carobbio A, Finazzi G, Vannucchi AM, Barosi G, Antonioli E, Guglielmelli P, Pancrazzi A, Salmoiraghi S, Zilio P, Ottomano C, Marchioli R, Cuccovillo I, Bottazzi B, Mantovani A, Rambaldi A, AGIMM and IIC Investigators. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica, 2011, no.2, pp.315–8. https://doi.org/10.3324/haematol.2010.031070

10. Dati F, Johnson AM, Whicher JT. The Existing Interim Consensus Reference Ranges and the Future Approach. Clinical Chemistry and Laboratory Medicine, 2001, no.11. https://doi.org/10.1515/CCLM.2001.179

11. Barbui T, Carobbio A, Bottazzi B, Zilio P, Salvi A, Cuccovillo I, Salmoiraghi S, Finazzi G, Mantovani A, Rambaldi A. High-Sensitivity C-Reactive Protein (hs-CRP) and Pentraxin 3 (PTX3) Are Increased in Essential Thrombocythemia and Polycythemia Vera. Blood, 2009, no.22, pp.1911. https://doi.org/10.1182/blood.V114.22.1911.1911

12. Hermouet S, Bigot-Corbel E, Gardie B. Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation. Giovarelli M, editor. Mediators of Inflammation, 2015, no.1, pp.145293. https://doi.org/10.1155/2015/145293

13. Campanelli R, Massa M, Rosti V, Barosi G. New Markers of Disease Progression in Myelofibrosis. Cancers, Multidisciplinary Digital Publishing Institute; 2021, no.21, pp.5324. https://doi.org/10.3390/cancers13215324

14. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-Reactive Protein Levels in Overweight and Obese Adults. JAMA, 1999, no.22, pp.2131–5. https://doi.org/10.1001/jama.282.22.2131